{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":15,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":15,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"9373f12a084b","filters":{"venue":"touchREVIEWS in Neurology"}},"results":[{"id":"W2802999705","doi":"10.17925/usn.2018.14.1.47","title":"Edaravone in Amyotrophic Lateral Sclerosis’Lessons from the Clinical Development Program and the Importance of a Strategic Clinical Trial Design","year":2018,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Amyotrophic Lateral Sclerosis Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Mitsubishi Tanabe Pharma Corporation; Mallinckrodt Pharmaceuticals","keywords":"Edaravone; Amyotrophic lateral sclerosis; Medicine; Clinical trial; Drug development; Clinical study design; Cohort; Disease; Intensive care medicine; Oncology; Pharmacology; Internal medicine; Drug","authors":[{"name":"Said R. Beydoun","is_ca":false},{"name":"Jeffrey Rosenfeld","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.4502577553450474,"gpt":0.4830974873236365,"spread":0.03283973197858914,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.131096,0.0006891697,0.002152228,0.0007930089,0.0006168461,0.003603487,0.002062977,0.004704923,0.00180035],"category_scores_gemma":[0.09495792,0.0004069407,0.001785334,0.0009729397,0.003744541,0.003960671,0.002501948,0.007506285,0.0004803689],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003178928,"about_ca_system_score_gemma":0.0140293,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001090639,"about_ca_topic_score_gemma":0.002084128,"domain_scores_codex":[0.9442729,0.0456265,0.003846706,0.001476738,0.004028655,0.0007484742],"domain_scores_gemma":[0.8904079,0.09041123,0.003768638,0.003525733,0.009089971,0.002796448],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.002974491,0.0003010648,0.001374785,0.01328246,0.001082469,0.0003847956,0.0006159689,0.001418485,0.001547717,0.09246378,0.05497918,0.8295748],"study_design_scores_gemma":[0.007781409,0.005356706,0.004489246,0.03265109,0.002187116,0.001107815,0.000520397,0.001900034,0.002578026,0.1231251,0.8181364,0.0001665767],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"commentary","genre_scores_codex":[0.004112294,0.8041633,0.01345484,0.1629479,0.009306047,0.0009690125,0.0001714936,0.00009553372,0.00477963],"genre_scores_gemma":[0.07207469,0.6738924,0.08426763,0.149527,0.0126125,0.004147642,0.0003421573,0.0001463647,0.0029896],"genre_candidate":"commentary","genre_consensus":null,"teacher_disagreement_score":0.131096,"threshold_uncertainty_score":0.6933101,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2492235344","doi":"10.17925/usn.2014.10.02.2","title":"Pharmacologic Decision-making in the Treatment of Focal Epilepsy—A Critical Comparison of Antiepileptic Drugs","year":2014,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Deutsche Forschungsgemeinschaft; Eisai; Valeant Pharmaceuticals International; Pfizer; Upsher-Smith; GlaxoSmithKline; Epilepsy Foundation","keywords":"Medicine; Polypharmacy; Epilepsy; Tolerability; Intensive care medicine; Antiepileptic drug; Dosing; Concomitant; Drug; Clinical trial; Psychiatry; Pharmacology; Adverse effect; Surgery; Internal medicine","authors":[{"name":"Selim R. Benbadis","is_ca":false},{"name":"Hermann Stefan","is_ca":false},{"name":"Diego Morita","is_ca":false},{"name":"Bassel Abou‐Khalil","is_ca":false},{"name":"R. Edward Hogan","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05073822582231736,"gpt":0.4335016986172411,"spread":0.3827634727949238,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03608518,0.0009098241,0.002960786,0.002461584,0.001275345,0.007808264,0.001791355,0.003178931,0.003232938],"category_scores_gemma":[0.07350055,0.000459212,0.001331588,0.00142081,0.002816536,0.005299076,0.002559603,0.004533979,0.0006277915],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005505735,"about_ca_system_score_gemma":0.007523398,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001055611,"about_ca_topic_score_gemma":0.002335454,"domain_scores_codex":[0.9721701,0.01891427,0.003348349,0.0007811103,0.004234135,0.0005520415],"domain_scores_gemma":[0.9223866,0.06337047,0.005127967,0.001049079,0.006006618,0.002059289],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.002097251,0.0002570248,0.003797519,0.01608434,0.001182378,0.001627078,0.001425528,0.001710443,0.0008401711,0.03541841,0.03606171,0.8994981],"study_design_scores_gemma":[0.001555982,0.006628171,0.01957167,0.1245339,0.003934122,0.01230651,0.01020737,0.006220753,0.003282633,0.1105505,0.7007455,0.0004629376],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.007106307,0.9369978,0.002385938,0.04238798,0.002952591,0.0001614214,0.00004518812,0.00002108791,0.007941703],"genre_scores_gemma":[0.1251721,0.8225797,0.02071646,0.02066633,0.009046133,0.000429987,0.0001442526,0.00004234107,0.001202739],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.03608518,"threshold_uncertainty_score":0.190839,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2799778697","doi":"10.17925/usn.2018.14.1.35","title":"Homocysteine Lowering with B Vitamins for Stroke Prevention—A History","year":2018,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Folate and B Vitamins Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Western University","funders":"","keywords":"Medicine; Methylcobalamin; Vitamin B12; Cyanocobalamin; Stroke (engine); B vitamins; Homocysteine; Internal medicine; Renal function; Gastroenterology; Endocrinology","authors":[{"name":"J. David Spence","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05588673959660658,"gpt":0.3377961441035223,"spread":0.2819094045069158,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002876303,0.000579615,0.0008174626,0.0009615981,0.0007597495,0.00196131,0.0006101034,0.002402641,0.006150625],"category_scores_gemma":[0.004871415,0.0002474755,0.000661449,0.000992563,0.001085974,0.002280212,0.001378309,0.005929253,0.002792194],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001375589,"about_ca_system_score_gemma":0.001660923,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002362262,"about_ca_topic_score_gemma":0.003928008,"domain_scores_codex":[0.9988751,0.0004315063,0.0001237713,0.0001938838,0.0003138075,0.00006201072],"domain_scores_gemma":[0.9977124,0.001251338,0.0001455927,0.0001327087,0.0004841945,0.0002737701],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000643877,0.000316992,0.001652726,0.006089019,0.0002999759,0.0003030543,0.0002138814,0.0001838554,0.002001083,0.01688787,0.2226268,0.7487808],"study_design_scores_gemma":[0.0004925074,0.0008417423,0.003286036,0.00593504,0.0002788073,0.0005636801,0.0001055044,0.0001965126,0.001138915,0.01713831,0.9699695,0.00005359254],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00232044,0.8437933,0.001093263,0.1264355,0.01150296,0.00007845613,0.000315976,0.00005530527,0.01440486],"genre_scores_gemma":[0.02041021,0.7754112,0.003434444,0.1624469,0.02048152,0.0001562228,0.0004235073,0.00006563067,0.01717043],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.006150625,"threshold_uncertainty_score":0.02057594,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4246577497","doi":"10.17925/usn.2013.09.01.35","title":"Symptomatic Treatment in Multiple Sclerosis","year":2013,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Multiple sclerosis; Spasticity; Quality of life (healthcare); Depression (economics); Disease; Physical medicine and rehabilitation; Balance (ability); Gait; Sexual dysfunction; Physical therapy; Psychiatry; Internal medicine","authors":[{"name":"Sandra Bigi","is_ca":true},{"name":"E Ann Yeh","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1273064182057693,"gpt":0.327353612265473,"spread":0.2000471940597037,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003684741,0.0002649182,0.0006556179,0.0006290058,0.0003429168,0.000489263,0.0003522191,0.0005837607,0.004925922],"category_scores_gemma":[0.000625863,0.0000556392,0.0003985894,0.0005158788,0.0001927265,0.0003183605,0.0003526428,0.0007331738,0.0009731324],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003355714,"about_ca_system_score_gemma":0.0003874211,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004902224,"about_ca_topic_score_gemma":0.001157164,"domain_scores_codex":[0.9997848,0.00007715957,0.00003014682,0.00002313576,0.00006714336,0.0000177203],"domain_scores_gemma":[0.999856,0.00005825164,0.00003214964,0.000005910099,0.00003052978,0.00001712907],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005343715,0.0002763985,0.00058306,0.01426288,0.0001923713,0.0005456341,0.0002075414,0.00007870754,0.004463355,0.00186956,0.02207357,0.9549125],"study_design_scores_gemma":[0.001003866,0.002818943,0.02007601,0.02025509,0.0009916757,0.01073489,0.0004125936,0.0002201927,0.004613847,0.005629591,0.9331943,0.00004891698],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.005312651,0.9842548,0.0003286924,0.001301432,0.0005737978,0.00003459338,0.00007365191,0.00003331175,0.008087002],"genre_scores_gemma":[0.09059641,0.8988845,0.001538638,0.003071318,0.00124832,0.0001397463,0.0003204638,0.00001745244,0.004183186],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.004925922,"threshold_uncertainty_score":0.0164789,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2487736606","doi":"10.17925/usn.2015.11.01.47","title":"Chronic Inflammatory Demyelinating Polyneuropathy in Diabetes Patients","year":2015,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Peripheral Neuropathies and Disorders","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University of Toronto; University Health Network","funders":"Eisai; Grifols; CSL Behring; Pfizer; Eli Lilly and Company","keywords":"Medicine; Chronic inflammatory demyelinating polyneuropathy; Polyneuropathy; Weakness; Diabetes mellitus; Polyradiculoneuropathy; Pathophysiology; Internal medicine; Nerve conduction velocity; Gastroenterology; Surgery; Pediatrics; Guillain-Barre syndrome; Immunology; Antibody; Endocrinology","authors":[{"name":"Alon Abraham","is_ca":true},{"name":"Majed Alabdali","is_ca":true},{"name":"Mohammad Qrimli","is_ca":true},{"name":"Carolina Barnett","is_ca":true},{"name":"Hans Katzberg","is_ca":true},{"name":"Bruce A. Perkins","is_ca":true},{"name":"Vera Bril","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01984212578548503,"gpt":0.2651941285470983,"spread":0.2453520027616133,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003504672,0.0002092776,0.0003265341,0.0005789439,0.0003752421,0.000548167,0.0001643814,0.0005006781,0.005494629],"category_scores_gemma":[0.0007959753,0.00007969709,0.0001723456,0.001072226,0.0001595803,0.000356353,0.0003963488,0.0005568065,0.0007902289],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003291169,"about_ca_system_score_gemma":0.000435964,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002263579,"about_ca_topic_score_gemma":0.002650907,"domain_scores_codex":[0.9998054,0.00005790204,0.00002929895,0.00002142786,0.00003952502,0.00004642295],"domain_scores_gemma":[0.9997057,0.00006581048,0.00007330684,0.000008057161,0.00004227912,0.0001047557],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.0004362866,0.0001796267,0.3582991,0.002458663,0.0001876098,0.0060186,0.0008346032,0.0001447817,0.001592036,0.002127582,0.09735888,0.5303622],"study_design_scores_gemma":[0.00009802538,0.0002614737,0.6733474,0.005530633,0.0002270113,0.02445474,0.001505263,0.0001664776,0.0003783248,0.002521217,0.2914797,0.00002964617],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.1087798,0.8016347,0.0004661412,0.02699873,0.00268289,0.00007494664,0.000764564,0.00008434428,0.058514],"genre_scores_gemma":[0.4380163,0.5345877,0.001071549,0.01059974,0.00499009,0.00007746778,0.001152969,0.00001452628,0.009489489],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.005494629,"threshold_uncertainty_score":0.01838136,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4247336648","doi":"10.17925/usn.2011.07.01.41","title":"Stroke Rehabilitation—An Overview of Existing Guidelines and Standards of Care","year":2011,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Stroke Rehabilitation and Recovery","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Rehabilitation; Guideline; Stroke (engine); Best evidence; Health care; Clinical Practice; Alternative medicine; MEDLINE; Physical therapy; Intensive care medicine; Pathology","authors":[{"name":"Richard D. Zorowitz","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2034381036885166,"gpt":0.431363879434349,"spread":0.2279257757458323,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02241606,0.001351209,0.002344493,0.01174294,0.002078499,0.005210067,0.005207414,0.004722368,0.004431063],"category_scores_gemma":[0.04477261,0.0009606769,0.002038336,0.015135,0.001454266,0.004321991,0.002739578,0.005429296,0.002684067],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.009357534,"about_ca_system_score_gemma":0.02953453,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02335833,"about_ca_topic_score_gemma":0.0462259,"domain_scores_codex":[0.9783584,0.006521035,0.007514708,0.0006308493,0.006312125,0.0006629661],"domain_scores_gemma":[0.9756939,0.007045676,0.003421191,0.0006145899,0.01218916,0.001035492],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008731834,0.0002125646,0.002603891,0.01776776,0.0002375513,0.0003469078,0.00079916,0.0009629626,0.0003154318,0.009864965,0.2823157,0.6844859],"study_design_scores_gemma":[0.00009088228,0.0001345058,0.008711562,0.1059942,0.0005148443,0.001040389,0.001496113,0.0009865385,0.0003154225,0.009319148,0.8712851,0.0001111968],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002691904,0.8107749,0.01755521,0.1254787,0.007320124,0.002187202,0.002765437,0.0006572417,0.0305692],"genre_scores_gemma":[0.01419312,0.8438449,0.1067081,0.02040665,0.002499017,0.002732851,0.005512888,0.0002134519,0.003889065],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.02335833,"threshold_uncertainty_score":0.1185489,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4255101771","doi":"10.17925/usn.2012.08.01.12","title":"Deep Brain Stimulation for Parkinson’s Disease—A Review","year":2012,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Neurological disorders and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre for Movement Disorders; University of British Columbia","funders":"","keywords":"Deep brain stimulation; Medicine; Dyskinesia; Parkinson's disease; Disease; Intervention (counseling); Motor symptoms; Medical therapy; Physical medicine and rehabilitation; Refractory (planetary science); Intensive care medicine; Physical therapy; Neuroscience; Psychiatry; Surgery; Psychology; Pathology","authors":[{"name":"Christopher R. Honey","is_ca":true},{"name":"Manish Ranjan","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04919421020952607,"gpt":0.344750848154001,"spread":0.2955566379444749,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007593268,0.0007694209,0.001339575,0.001578032,0.000268843,0.0008418618,0.0007747997,0.001105915,0.002713075],"category_scores_gemma":[0.001249857,0.000223557,0.0004725064,0.001825072,0.0004574411,0.001158154,0.0004038875,0.001009548,0.001408768],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004508013,"about_ca_system_score_gemma":0.0006530095,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009042796,"about_ca_topic_score_gemma":0.001599255,"domain_scores_codex":[0.9997348,0.00006107218,0.00006303985,0.00003288736,0.00009357307,0.00001458266],"domain_scores_gemma":[0.9993524,0.0004379999,0.00007597858,0.00001588335,0.00008796287,0.00002983587],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"systematic_review","study_design_scores_codex":[0.00007206243,0.00008501353,0.0002348788,0.01753999,0.0001332708,0.0005400371,0.00007373343,0.000327229,0.0009788119,0.00136528,0.03356334,0.9450864],"study_design_scores_gemma":[0.00005947857,0.0003235937,0.00294998,0.02360417,0.0002834162,0.006817166,0.0001717723,0.0002019222,0.0006577526,0.002774178,0.9621231,0.00003353551],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000101866,0.9988826,0.00006594885,0.0001970242,0.000283406,0.000004194301,0.000003294522,0.000002570773,0.0004591098],"genre_scores_gemma":[0.0005926946,0.998266,0.0001327547,0.0002922525,0.0003849122,0.000006078634,0.000007629827,0.000001273291,0.0003163114],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002713075,"threshold_uncertainty_score":0.009076178,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2482237976","doi":"10.17925/usn.2015.11.01.19","title":"Physical Activity in Pediatric Multiple Sclerosis—Can Lifestyle Factors Affect Disease Outcomes?","year":2015,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Hospital for Sick Children; Multiple Sclerosis Society; Multiple Sclerosis Society of Canada; Canadian Institutes of Health Research; Multiple Sclerosis Scientific Research Foundation; Public Health Agency; Dairy Farmers of Ontario; Public Health Agency of Canada; EMD Serono; National Multiple Sclerosis Society","keywords":"Medicine; Affect (linguistics); Multiple sclerosis; Depression (economics); Disease; Psychological intervention; Neuroinflammation; Population; Cognition; Physical activity; Physical therapy; Physical medicine and rehabilitation; Clinical psychology; Gerontology; Psychiatry; Psychology; Environmental health; Internal medicine","authors":[{"name":"E. Ann Yeh","is_ca":true},{"name":"Robert W. Motl","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1576437093915405,"gpt":0.3693103030240867,"spread":0.2116665936325463,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008985063,0.0002933018,0.0008967338,0.001003777,0.0002082172,0.0009765858,0.000388707,0.0006006062,0.001761829],"category_scores_gemma":[0.002889109,0.0001450394,0.0005600621,0.001194659,0.0003876934,0.0006791843,0.0005423056,0.001023875,0.0003275131],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000442905,"about_ca_system_score_gemma":0.0005100345,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00310628,"about_ca_topic_score_gemma":0.004372563,"domain_scores_codex":[0.9994023,0.0002379919,0.0000874565,0.0001094497,0.0001232294,0.00003963082],"domain_scores_gemma":[0.9988903,0.0006686141,0.0002303339,0.00002603565,0.0001266843,0.00005807258],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003296933,0.0002029915,0.09698399,0.01717106,0.001085355,0.0004539469,0.0009581901,0.0003117067,0.0008214113,0.002265865,0.009659476,0.8697564],"study_design_scores_gemma":[0.00007716769,0.0009733494,0.7161745,0.04931118,0.002575655,0.002805015,0.002367218,0.0003985447,0.0008750075,0.004967425,0.219391,0.00008400248],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01291435,0.9821995,0.0001463681,0.003158489,0.0002508033,0.000008885934,0.0001275222,0.000004517267,0.001189509],"genre_scores_gemma":[0.06235041,0.9351279,0.0004572095,0.0009620228,0.0005767177,0.00003425691,0.0001616855,0.000005165031,0.0003246718],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.00310628,"threshold_uncertainty_score":0.006176353,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4212945886","doi":"10.17925/usn.2021.17.2.70","title":"Innovative Therapeutic Development Programme for the Treatment of Early Alzheimer's Disease: Lecanemab (BAN2401)","year":2021,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Cholinesterase and Neurodegenerative Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Resverlogix (Canada)","funders":"National Institute of Neurological Disorders and Stroke; National Institute of General Medical Sciences; National Institute on Aging","keywords":"Disease; Alzheimer's disease; Medicine; Internal medicine","authors":[{"name":"Jeffrey L. Cummings","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1204789983611148,"gpt":0.3635085386470207,"spread":0.2430295402859059,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009903876,0.0004741349,0.0002683428,0.0004877429,0.0003648413,0.0008040603,0.0005952601,0.0009776405,0.01561483],"category_scores_gemma":[0.0004447355,0.0000820096,0.0003988405,0.0002581683,0.0002843094,0.0004884378,0.0007200228,0.00121711,0.005046013],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008380053,"about_ca_system_score_gemma":0.001621675,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00124053,"about_ca_topic_score_gemma":0.002340688,"domain_scores_codex":[0.9997754,0.00005252452,0.00001177903,0.0000303764,0.00006552909,0.00006441375],"domain_scores_gemma":[0.9997361,0.00002938789,0.0000326142,0.00001070101,0.00005815808,0.0001329733],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001434302,0.0007674256,0.0008214264,0.0008910613,0.00006798725,0.0005927373,0.00006958227,0.0002414374,0.03116534,0.006858561,0.1480519,0.8090383],"study_design_scores_gemma":[0.001568756,0.003601541,0.005210083,0.0004029299,0.0001434381,0.00173591,0.00004854055,0.0004771016,0.03437657,0.002199253,0.9502023,0.00003358598],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.1119707,0.4237529,0.01646782,0.1066037,0.01949528,0.00217107,0.005878369,0.002312174,0.3113481],"genre_scores_gemma":[0.3077289,0.2752835,0.02814161,0.03989932,0.008035456,0.001580706,0.008303029,0.0003639339,0.3306636],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01561483,"threshold_uncertainty_score":0.05223686,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W32808450","doi":"10.17925/usn.2010.06.01.36","title":"Monoamine Oxidase Type B Inhibitors in the Treatment of Early Parkinson’s Disease","year":2010,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre for Movement Disorders","funders":"National Institutes of Health; Ipsen; Teva Pharmaceutical Industries","keywords":"Medicine; Levodopa; Carbidopa; Monoamine oxidase B; Parkinson's disease; Monoamine oxidase; Disease; Selegiline; Pharmacology; Pharmacotherapy; Dopamine; Internal medicine; Enzyme","authors":[{"name":"Cherian Abraham Karunapuzha","is_ca":true},{"name":"Shilpa Chitnis","is_ca":false},{"name":"Richard B. Dewey","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02569942357868454,"gpt":0.2946161251388231,"spread":0.2689167015601386,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008652037,0.0003534624,0.000673843,0.0007236593,0.0002356403,0.0005484304,0.0003824838,0.00117939,0.002089978],"category_scores_gemma":[0.0006148645,0.0001285763,0.0002265063,0.0005620294,0.0002858854,0.0005242325,0.0002633475,0.0009108603,0.0008253759],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004132245,"about_ca_system_score_gemma":0.0004684379,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007541354,"about_ca_topic_score_gemma":0.002026052,"domain_scores_codex":[0.9997651,0.00008029713,0.00002532584,0.00002132178,0.00008258328,0.0000254326],"domain_scores_gemma":[0.9997668,0.0001050309,0.00004958794,0.000005516348,0.00003848398,0.00003458839],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005346001,0.0001708421,0.0013112,0.00355644,0.0001021549,0.001799401,0.0001724696,0.0002047018,0.004066651,0.00227234,0.02359438,0.9622148],"study_design_scores_gemma":[0.0005442516,0.002062387,0.01866237,0.003841181,0.0003622083,0.01342626,0.0003724781,0.0002613084,0.003667221,0.004722256,0.9520417,0.0000364031],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001780161,0.9939864,0.00008184506,0.001391365,0.000290662,0.000005026759,0.000004203537,0.00000669941,0.002453648],"genre_scores_gemma":[0.01432183,0.9812087,0.0003207459,0.0009738703,0.001009525,0.000009816469,0.00001030964,0.000002128213,0.002143098],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002089978,"threshold_uncertainty_score":0.006991684,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2490618669","doi":"10.17925/usn.2014.10.02.90","title":"Magnetic Resonance Imaging and Dopamine Transporter Single Photon Emission Tomography in Parkinson’s Disease—When Should We Use Them?","year":2014,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre for Movement Disorders","funders":"","keywords":"Medicine; Magnetic resonance imaging; Dopamine transporter; Parkinson's disease; Disease; Medical diagnosis; Dopamine; Radiology; Pathology; Internal medicine; Dopaminergic","authors":[{"name":"Meir Kestenbaum","is_ca":true},{"name":"Cheryl Waters","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03341976575299417,"gpt":0.2601324053259612,"spread":0.2267126395729671,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007497394,0.00075509,0.002038384,0.001916003,0.0008910304,0.003043237,0.001232015,0.00569552,0.00316239],"category_scores_gemma":[0.02198432,0.0005573122,0.0007760625,0.001044894,0.002274272,0.00518669,0.001102442,0.006838701,0.001792993],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001279147,"about_ca_system_score_gemma":0.001591878,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003047833,"about_ca_topic_score_gemma":0.005900991,"domain_scores_codex":[0.9968686,0.001322507,0.0004553351,0.0001835082,0.001026158,0.0001439256],"domain_scores_gemma":[0.987829,0.006782977,0.001036412,0.0004380031,0.003071431,0.0008422544],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004924173,0.0001676482,0.01598267,0.003009156,0.0005825129,0.00330445,0.0004762441,0.0002330302,0.001397191,0.007953668,0.2693064,0.6970947],"study_design_scores_gemma":[0.0002358595,0.0005152122,0.04379224,0.02189966,0.0007712963,0.01416516,0.002287706,0.0006525709,0.0007584953,0.03008026,0.8846133,0.0002281864],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002293772,0.8431636,0.0005837608,0.1410184,0.009059974,0.00001512715,0.00003619718,0.00003662104,0.003792555],"genre_scores_gemma":[0.0312139,0.866509,0.003211202,0.05308746,0.04215824,0.00005023633,0.00007254633,0.00004912476,0.003648302],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.007497394,"threshold_uncertainty_score":0.0396505,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2944875226","doi":"10.17925/usn.2019.15.1.18","title":"Imaging, Technology, and Parkinson’s Disease","year":2019,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Neurological disorders and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre for Movement Disorders","funders":"","keywords":"Deep brain stimulation; Medicine; Movement disorders; Dystonia; Essential tremor; Neuromodulation; Parkinson's disease; Neuroimaging; Translational research; Neurosurgery; Neurology; Clinical neuroscience; Neuroscience; Physical medicine and rehabilitation; Disease; Psychology; Psychiatry; Pathology; Internal medicine","authors":[{"name":"Nora Vanegas","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01212401069292168,"gpt":0.2724420969306564,"spread":0.2603180862377347,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009380933,0.0004474995,0.000457044,0.001522158,0.0007132299,0.002258608,0.0006736404,0.002833842,0.009431401],"category_scores_gemma":[0.002611385,0.0002036548,0.0004285141,0.00115698,0.002230652,0.001768527,0.001091378,0.003069102,0.00234752],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001948493,"about_ca_system_score_gemma":0.00109298,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005185333,"about_ca_topic_score_gemma":0.007586896,"domain_scores_codex":[0.9992093,0.000201417,0.00005910471,0.00008740051,0.0003464302,0.0000963924],"domain_scores_gemma":[0.9988006,0.0006566753,0.0001049435,0.00004870653,0.0002744236,0.0001146835],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00003472311,0.00005018185,0.0009340057,0.001720145,0.00007731539,0.0006352571,0.0003753581,0.0001396644,0.0008343289,0.03361763,0.6688985,0.2926829],"study_design_scores_gemma":[0.000006952912,0.00002770388,0.002461897,0.001542941,0.00002496434,0.001665534,0.0003222775,0.0000336617,0.0002249415,0.01372417,0.979952,0.00001285633],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0004579086,0.9283756,0.0001277487,0.04681973,0.008256965,0.000005307325,0.00002143986,0.00001822142,0.01591704],"genre_scores_gemma":[0.01071403,0.9273646,0.0003997732,0.02595219,0.0173327,0.00001417726,0.00005694059,0.00002200319,0.01814371],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.009431401,"threshold_uncertainty_score":0.03155112,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2494387052","doi":"10.17925/usn.2010.06.02.96","title":"Environmental Risk Factors for Pediatric Multiple Sclerosis","year":2010,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Carcinogens and Genotoxicity Assessment","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Multiple sclerosis; Medicine; Disease; Environmental health; Immunology; Pathology","authors":[{"name":"Naila Makhani","is_ca":true},{"name":"Brenda Banwell","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02081325690780442,"gpt":0.2430942109713232,"spread":0.2222809540635188,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000227942,0.0002612197,0.0002785439,0.0005621524,0.0002121471,0.0003526208,0.000144681,0.0003451303,0.00224451],"category_scores_gemma":[0.0006349047,0.00008712474,0.0002083663,0.000658422,0.0001736986,0.0001762569,0.0002565408,0.0004661417,0.000239595],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002267807,"about_ca_system_score_gemma":0.0003535938,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002335798,"about_ca_topic_score_gemma":0.002600561,"domain_scores_codex":[0.9998147,0.00005450941,0.00001345194,0.00003110459,0.00006173734,0.0000245385],"domain_scores_gemma":[0.9996235,0.0001339932,0.0001392975,0.00001053332,0.00004974803,0.00004286533],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001777733,0.0001150393,0.7589133,0.0005746785,0.0003398573,0.004223234,0.000431448,0.0004438738,0.003995213,0.00278882,0.008970113,0.2190267],"study_design_scores_gemma":[0.000009793196,0.0001420634,0.9257413,0.0007606588,0.0003160322,0.01096454,0.0003164806,0.0002602135,0.001162619,0.001610582,0.05870068,0.00001503999],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.4152304,0.5475366,0.002535556,0.007761328,0.0003342776,0.00003601195,0.000807644,0.0001137303,0.02564446],"genre_scores_gemma":[0.7236076,0.2670241,0.00305945,0.0007477527,0.0005478192,0.00003560608,0.0005091197,0.00002244136,0.004445965],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002335798,"threshold_uncertainty_score":0.007508636,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4210542383","doi":"10.17925/usn.2009.05.01.75","title":"Advances in Medical Management of Cluster Headache","year":2009,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Innovation Cluster (Canada)","funders":"","keywords":"Medicine; Cluster headache; Sumatriptan; Zolmitriptan; Methysergide; Topiramate; Triptans; Tolerability; Anesthesia; Verapamil; Migraine; Rizatriptan; Epilepsy; Internal medicine; Adverse effect; Agonist","authors":[{"name":"Stefan Evers","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02287596340054963,"gpt":0.3577844737415116,"spread":0.334908510340962,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002686738,0.0004060731,0.0006271537,0.001655931,0.0003479339,0.0009920318,0.0006948235,0.001105923,0.005308611],"category_scores_gemma":[0.003658828,0.0001386221,0.000449781,0.00119354,0.0006679075,0.001618318,0.0006409043,0.001651567,0.001361162],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00102454,"about_ca_system_score_gemma":0.001389533,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00177748,"about_ca_topic_score_gemma":0.003420182,"domain_scores_codex":[0.9992018,0.0002697356,0.0001117224,0.00008194687,0.0002781748,0.00005660277],"domain_scores_gemma":[0.9968987,0.001498102,0.0003238668,0.0001340926,0.0008908967,0.0002543582],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002043712,0.0002438954,0.001326612,0.004658763,0.00008382003,0.0003618693,0.0001284899,0.0001928217,0.0006589266,0.005600353,0.03486667,0.9516734],"study_design_scores_gemma":[0.0001478156,0.0005276021,0.007126688,0.003915582,0.000167211,0.002161031,0.0002229891,0.0001781398,0.0004494936,0.006307802,0.9787677,0.00002792457],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001316965,0.9757794,0.0004815363,0.01302139,0.001456268,0.00001391064,0.00002738419,0.00001793616,0.007885189],"genre_scores_gemma":[0.01023443,0.9760751,0.002223279,0.004051757,0.005845711,0.00002080392,0.00005637893,0.000006045471,0.001486434],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005308611,"threshold_uncertainty_score":0.01775903,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4249026402","doi":"10.17925/usn.2011.07.02.84","title":"Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis—A Medical, Sociological, and Media Controversy","year":2011,"lang":"en","type":"article","venue":"touchREVIEWS in Neurology","topic":"Cerebral Venous Sinus Thrombosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Multiple sclerosis; Clinical trial; Skepticism; Intensive care medicine; Internal medicine; Psychiatry","authors":[{"name":"Aaron Miller","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1034316384392937,"gpt":0.2793572829191007,"spread":0.175925644479807,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.01154799,0.0004298036,0.001114732,0.005264102,0.008241088,0.01140128,0.001569303,0.01225032,0.005442598],"category_scores_gemma":[0.03306953,0.0005123395,0.0007047944,0.003940094,0.01715672,0.01230243,0.004894007,0.01281852,0.001108623],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006032227,"about_ca_system_score_gemma":0.004504683,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008390168,"about_ca_topic_score_gemma":0.0074817,"domain_scores_codex":[0.9936237,0.003050341,0.0005596757,0.0006813906,0.001430055,0.0006548925],"domain_scores_gemma":[0.9609717,0.02776879,0.004004795,0.0008243996,0.003759109,0.002671338],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"qualitative","study_design_scores_codex":[0.0004373389,0.0002769715,0.01450019,0.002652237,0.0002284855,0.00426729,0.03596371,0.0001008346,0.0006523223,0.129881,0.5285158,0.282524],"study_design_scores_gemma":[0.0001328137,0.0001548499,0.01839949,0.009254384,0.000189439,0.007220748,0.02802266,0.0001476627,0.0002745088,0.04065597,0.8953749,0.0001726058],"study_design_candidate":"qualitative","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.006310589,0.1853262,0.00009169627,0.7915426,0.01057612,0.000007489926,0.00006873572,0.00001229341,0.00606431],"genre_scores_gemma":[0.16782,0.2762592,0.0003731964,0.423231,0.1290919,0.00004988482,0.0001242215,0.00004512235,0.00300553],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.9917589,"threshold_uncertainty_score":0.06107235,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}